Diabetes Drugs Market
Diabetes Drugs Market - Global Industry Assessment & Forecast
#
Pages:
210
Base Year:
2024
Nov - 2024
Format:
Report Code:
VMR-3023
Segments Covered
By
Drug Class Insulin, GLP-1 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Biguanides (Metformin), Others (Thiazolidinediones, Meglitinides)
-
By
Diabetes Type Type 1 Diabetes, Type 2 Diabetes, Gestational Diabetes
-
By
Route of Administration Oral, Injectable
-
By
Distribution Channel Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Clinics
-
By
Region North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Snapshot
 Base Year:
|
2024 |
| Forecast
Years:
|
2025 - 2034 |
 Historical
Years:
|
2019 - 2023 |
 Revenue
2024: |
USD 84.65 Billion |
 Revenue 2034:
|
USD 177.74 Billion |
 Revenue CAGR
(2025 - 2034): |
7.7% |
Fastest Growing Region (2025 -
2034)
|
Asia Pacific |
Largest Region (2024):
|
North America |
Customization Offered
Cross-segment Market Size and
Analysis
for Mentioned Segments- Additional Company Profiles (Upto 5
With
No Cost)
- Additional Countries (Apart From
Mentioned Countries)
- Country/Region-specific Report
- Go To Market Strategy
- Region Specific Market Dynamics
- Region Level Market Share
- Import Export Analysis
- Production Analysis
- Others Request
Customization Speak To
Analyst
Diabetes Drugs Market Segment Analysis
- Diabetes Drugs Drug Class Outlook (Revenue, USD Million, 2018 - 2030)
- Insulin
- GLP-1 Receptor Agonists
- SGLT-2 Inhibitors
- DPP-4 Inhibitors
- Biguanides (Metformin)
- Others (Thiazolidinediones
- Meglitinides)
- Diabetes Drugs Diabetes Type Outlook (Revenue, USD Million, 2018 - 2030)
- Type 1 Diabetes
- Type 2 Diabetes
- Gestational Diabetes
- Diabetes Drugs Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
- Oral
- Injectable
- Diabetes Drugs Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Specialty Clinics
-
Regional Outlook (Revenue, USD Billion/Million, 2018 - 2030)
- North America
-
North America Diabetes Drugs Market, by Drug Class
- Insulin
- GLP-1 Receptor Agonists
- SGLT-2 Inhibitors
- DPP-4 Inhibitors
- Biguanides (Metformin)
- Others (Thiazolidinediones
- Meglitinides)
-
North America Diabetes Drugs Market, by Diabetes Type
- Type 1 Diabetes
- Type 2 Diabetes
- Gestational Diabetes
-
North America Diabetes Drugs Market, by Route of Administration
- Oral
- Injectable
-
North America Diabetes Drugs Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Specialty Clinics
- U.S.
- U.S. Diabetes Drugs Market, by Drug Class
- Insulin
- GLP-1 Receptor Agonists
- SGLT-2 Inhibitors
- DPP-4 Inhibitors
- Biguanides (Metformin)
- Others (Thiazolidinediones
- Meglitinides)
- U.S. Diabetes Drugs Market, by Diabetes Type
- Type 1 Diabetes
- Type 2 Diabetes
- Gestational Diabetes
- U.S. Diabetes Drugs Market, by Route of Administration
- Oral
- Injectable
- U.S. Diabetes Drugs Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Specialty Clinics
- U.S. Diabetes Drugs Market, by Drug Class
- Canada
- Canada Diabetes Drugs Market, by Drug Class
- Insulin
- GLP-1 Receptor Agonists
- SGLT-2 Inhibitors
- DPP-4 Inhibitors
- Biguanides (Metformin)
- Others (Thiazolidinediones
- Meglitinides)
- Canada Diabetes Drugs Market, by Diabetes Type
- Type 1 Diabetes
- Type 2 Diabetes
- Gestational Diabetes
- Canada Diabetes Drugs Market, by Route of Administration
- Oral
- Injectable
- Canada Diabetes Drugs Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Specialty Clinics
- Canada Diabetes Drugs Market, by Drug Class
-
Mexico
- Mexico Diabetes Drugs Market, by Drug Class
- Insulin
- GLP-1 Receptor Agonists
- SGLT-2 Inhibitors
- DPP-4 Inhibitors
- Biguanides (Metformin)
- Others (Thiazolidinediones
- Meglitinides)
- Mexico Diabetes Drugs Market, by Diabetes Type
- Type 1 Diabetes
- Type 2 Diabetes
- Gestational Diabetes
- Mexico Diabetes Drugs Market, by Route of Administration
- Oral
- Injectable
- Mexico Diabetes Drugs Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Specialty Clinics
- Mexico Diabetes Drugs Market, by Drug Class
-
North America Diabetes Drugs Market, by Drug Class
- Europe
-
Europe Diabetes Drugs Market, by Drug Class
- Insulin
- GLP-1 Receptor Agonists
- SGLT-2 Inhibitors
- DPP-4 Inhibitors
- Biguanides (Metformin)
- Others (Thiazolidinediones
- Meglitinides)
-
Europe Diabetes Drugs Market, by Diabetes Type
- Type 1 Diabetes
- Type 2 Diabetes
- Gestational Diabetes
-
Europe Diabetes Drugs Market, by Route of Administration
- Oral
- Injectable
-
Europe Diabetes Drugs Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Specialty Clinics
- U. K.
- U.K. Diabetes Drugs Market, by Drug Class
- Insulin
- GLP-1 Receptor Agonists
- SGLT-2 Inhibitors
- DPP-4 Inhibitors
- Biguanides (Metformin)
- Others (Thiazolidinediones
- Meglitinides)
- U.K. Diabetes Drugs Market, by Diabetes Type
- Type 1 Diabetes
- Type 2 Diabetes
- Gestational Diabetes
- U.K. Diabetes Drugs Market, by Route of Administration
- Oral
- Injectable
- U.K. Diabetes Drugs Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Specialty Clinics
- U.K. Diabetes Drugs Market, by Drug Class
- France
- France Diabetes Drugs Market, by Drug Class
- Insulin
- GLP-1 Receptor Agonists
- SGLT-2 Inhibitors
- DPP-4 Inhibitors
- Biguanides (Metformin)
- Others (Thiazolidinediones
- Meglitinides)
- France Diabetes Drugs Market, by Diabetes Type
- Type 1 Diabetes
- Type 2 Diabetes
- Gestational Diabetes
- France Diabetes Drugs Market, by Route of Administration
- Oral
- Injectable
- France Diabetes Drugs Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Specialty Clinics
- France Diabetes Drugs Market, by Drug Class
-
Germany
- Germany Diabetes Drugs Market, by Drug Class
- Insulin
- GLP-1 Receptor Agonists
- SGLT-2 Inhibitors
- DPP-4 Inhibitors
- Biguanides (Metformin)
- Others (Thiazolidinediones
- Meglitinides)
- Germany Diabetes Drugs Market, by Diabetes Type
- Type 1 Diabetes
- Type 2 Diabetes
- Gestational Diabetes
- Germany Diabetes Drugs Market, by Route of Administration
- Oral
- Injectable
- Germany Diabetes Drugs Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Specialty Clinics
- Germany Diabetes Drugs Market, by Drug Class
-
Italy
- Italy Diabetes Drugs Market, by Drug Class
- Insulin
- GLP-1 Receptor Agonists
- SGLT-2 Inhibitors
- DPP-4 Inhibitors
- Biguanides (Metformin)
- Others (Thiazolidinediones
- Meglitinides)
- Italy Diabetes Drugs Market, by Diabetes Type
- Type 1 Diabetes
- Type 2 Diabetes
- Gestational Diabetes
- Italy Diabetes Drugs Market, by Route of Administration
- Oral
- Injectable
- Italy Diabetes Drugs Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Specialty Clinics
- Italy Diabetes Drugs Market, by Drug Class
-
Spain
- Spain Diabetes Drugs Market, by Drug Class
- Insulin
- GLP-1 Receptor Agonists
- SGLT-2 Inhibitors
- DPP-4 Inhibitors
- Biguanides (Metformin)
- Others (Thiazolidinediones
- Meglitinides)
- Spain Diabetes Drugs Market, by Diabetes Type
- Type 1 Diabetes
- Type 2 Diabetes
- Gestational Diabetes
- Spain Diabetes Drugs Market, by Route of Administration
- Oral
- Injectable
- Spain Diabetes Drugs Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Specialty Clinics
- Spain Diabetes Drugs Market, by Drug Class
-
Rest of Europe
- Rest of Europe Diabetes Drugs Market, by Drug Class
- Insulin
- GLP-1 Receptor Agonists
- SGLT-2 Inhibitors
- DPP-4 Inhibitors
- Biguanides (Metformin)
- Others (Thiazolidinediones
- Meglitinides)
- Rest of Europe Diabetes Drugs Market, by Diabetes Type
- Type 1 Diabetes
- Type 2 Diabetes
- Gestational Diabetes
- Rest of Europe Diabetes Drugs Market, by Route of Administration
- Oral
- Injectable
- Rest of Europe Diabetes Drugs Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Specialty Clinics
- Rest of Europe Diabetes Drugs Market, by Drug Class
-
Europe Diabetes Drugs Market, by Drug Class
- Asia Pacific
-
Asia Pacific Diabetes Drugs Market, by Drug Class
- Insulin
- GLP-1 Receptor Agonists
- SGLT-2 Inhibitors
- DPP-4 Inhibitors
- Biguanides (Metformin)
- Others (Thiazolidinediones
- Meglitinides)
-
Asia Pacific Diabetes Drugs Market, by Diabetes Type
- Type 1 Diabetes
- Type 2 Diabetes
- Gestational Diabetes
-
Asia Pacific Diabetes Drugs Market, by Route of Administration
- Oral
- Injectable
-
Asia Pacific Diabetes Drugs Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Specialty Clinics
- China
- China Diabetes Drugs Market, by Drug Class
- Insulin
- GLP-1 Receptor Agonists
- SGLT-2 Inhibitors
- DPP-4 Inhibitors
- Biguanides (Metformin)
- Others (Thiazolidinediones
- Meglitinides)
- China Diabetes Drugs Market, by Diabetes Type
- Type 1 Diabetes
- Type 2 Diabetes
- Gestational Diabetes
- China Diabetes Drugs Market, by Route of Administration
- Oral
- Injectable
- China Diabetes Drugs Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Specialty Clinics
- China Diabetes Drugs Market, by Drug Class
- Japan
- Japan Diabetes Drugs Market, by Drug Class
- Insulin
- GLP-1 Receptor Agonists
- SGLT-2 Inhibitors
- DPP-4 Inhibitors
- Biguanides (Metformin)
- Others (Thiazolidinediones
- Meglitinides)
- Japan Diabetes Drugs Market, by Diabetes Type
- Type 1 Diabetes
- Type 2 Diabetes
- Gestational Diabetes
- Japan Diabetes Drugs Market, by Route of Administration
- Oral
- Injectable
- Japan Diabetes Drugs Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Specialty Clinics
- Japan Diabetes Drugs Market, by Drug Class
-
Germany
- Germany Diabetes Drugs Market, by Drug Class
- Insulin
- GLP-1 Receptor Agonists
- SGLT-2 Inhibitors
- DPP-4 Inhibitors
- Biguanides (Metformin)
- Others (Thiazolidinediones
- Meglitinides)
- Germany Diabetes Drugs Market, by Diabetes Type
- Type 1 Diabetes
- Type 2 Diabetes
- Gestational Diabetes
- Germany Diabetes Drugs Market, by Route of Administration
- Oral
- Injectable
- Germany Diabetes Drugs Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Specialty Clinics
- Germany Diabetes Drugs Market, by Drug Class
-
India
- India Diabetes Drugs Market, by Drug Class
- Insulin
- GLP-1 Receptor Agonists
- SGLT-2 Inhibitors
- DPP-4 Inhibitors
- Biguanides (Metformin)
- Others (Thiazolidinediones
- Meglitinides)
- India Diabetes Drugs Market, by Diabetes Type
- Type 1 Diabetes
- Type 2 Diabetes
- Gestational Diabetes
- India Diabetes Drugs Market, by Route of Administration
- Oral
- Injectable
- India Diabetes Drugs Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Specialty Clinics
- India Diabetes Drugs Market, by Drug Class
-
South Korea
- South Korea Diabetes Drugs Market, by Drug Class
- Insulin
- GLP-1 Receptor Agonists
- SGLT-2 Inhibitors
- DPP-4 Inhibitors
- Biguanides (Metformin)
- Others (Thiazolidinediones
- Meglitinides)
- South Korea Diabetes Drugs Market, by Diabetes Type
- Type 1 Diabetes
- Type 2 Diabetes
- Gestational Diabetes
- South Korea Diabetes Drugs Market, by Route of Administration
- Oral
- Injectable
- South Korea Diabetes Drugs Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Specialty Clinics
- South Korea Diabetes Drugs Market, by Drug Class
-
South East Asia
- South East Asia Diabetes Drugs Market, by Drug Class
- Insulin
- GLP-1 Receptor Agonists
- SGLT-2 Inhibitors
- DPP-4 Inhibitors
- Biguanides (Metformin)
- Others (Thiazolidinediones
- Meglitinides)
- South East Asia Diabetes Drugs Market, by Diabetes Type
- Type 1 Diabetes
- Type 2 Diabetes
- Gestational Diabetes
- South East Asia Diabetes Drugs Market, by Route of Administration
- Oral
- Injectable
- South East Asia Diabetes Drugs Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Specialty Clinics
- South East Asia Diabetes Drugs Market, by Drug Class
-
Rest of Asia Pacific
- Rest of Asia Pacific Diabetes Drugs Market, by Drug Class
- Insulin
- GLP-1 Receptor Agonists
- SGLT-2 Inhibitors
- DPP-4 Inhibitors
- Biguanides (Metformin)
- Others (Thiazolidinediones
- Meglitinides)
- Rest of Asia Pacific Diabetes Drugs Market, by Diabetes Type
- Type 1 Diabetes
- Type 2 Diabetes
- Gestational Diabetes
- Rest of Asia Pacific Diabetes Drugs Market, by Route of Administration
- Oral
- Injectable
- Rest of Asia Pacific Diabetes Drugs Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Specialty Clinics
- Rest of Asia Pacific Diabetes Drugs Market, by Drug Class
-
Asia Pacific Diabetes Drugs Market, by Drug Class
- Latin America
-
Latin America Diabetes Drugs Market, by Drug Class
- Insulin
- GLP-1 Receptor Agonists
- SGLT-2 Inhibitors
- DPP-4 Inhibitors
- Biguanides (Metformin)
- Others (Thiazolidinediones
- Meglitinides)
-
Latin America Diabetes Drugs Market, by Diabetes Type
- Type 1 Diabetes
- Type 2 Diabetes
- Gestational Diabetes
-
Latin America Diabetes Drugs Market, by Route of Administration
- Oral
- Injectable
-
Latin America Diabetes Drugs Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Specialty Clinics
- Brazil
- Brazil Diabetes Drugs Market, by Drug Class
- Insulin
- GLP-1 Receptor Agonists
- SGLT-2 Inhibitors
- DPP-4 Inhibitors
- Biguanides (Metformin)
- Others (Thiazolidinediones
- Meglitinides)
- Brazil Diabetes Drugs Market, by Diabetes Type
- Type 1 Diabetes
- Type 2 Diabetes
- Gestational Diabetes
- Brazil Diabetes Drugs Market, by Route of Administration
- Oral
- Injectable
- Brazil Diabetes Drugs Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Specialty Clinics
- Brazil Diabetes Drugs Market, by Drug Class
- Argentina
- Argentina Diabetes Drugs Market, by Drug Class
- Insulin
- GLP-1 Receptor Agonists
- SGLT-2 Inhibitors
- DPP-4 Inhibitors
- Biguanides (Metformin)
- Others (Thiazolidinediones
- Meglitinides)
- Argentina Diabetes Drugs Market, by Diabetes Type
- Type 1 Diabetes
- Type 2 Diabetes
- Gestational Diabetes
- Argentina Diabetes Drugs Market, by Route of Administration
- Oral
- Injectable
- Argentina Diabetes Drugs Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Specialty Clinics
- Argentina Diabetes Drugs Market, by Drug Class
-
Rest of Latin America
- Rest of Latin America Diabetes Drugs Market, by Drug Class
- Insulin
- GLP-1 Receptor Agonists
- SGLT-2 Inhibitors
- DPP-4 Inhibitors
- Biguanides (Metformin)
- Others (Thiazolidinediones
- Meglitinides)
- Rest of Latin America Diabetes Drugs Market, by Diabetes Type
- Type 1 Diabetes
- Type 2 Diabetes
- Gestational Diabetes
- Rest of Latin America Diabetes Drugs Market, by Route of Administration
- Oral
- Injectable
- Rest of Latin America Diabetes Drugs Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Specialty Clinics
- Rest of Latin America Diabetes Drugs Market, by Drug Class
-
Latin America Diabetes Drugs Market, by Drug Class
- Middle East & Africa
-
Middle East & Africa Diabetes Drugs Market, by Drug Class
- Insulin
- GLP-1 Receptor Agonists
- SGLT-2 Inhibitors
- DPP-4 Inhibitors
- Biguanides (Metformin)
- Others (Thiazolidinediones
- Meglitinides)
-
Middle East & Africa Diabetes Drugs Market, by Diabetes Type
- Type 1 Diabetes
- Type 2 Diabetes
- Gestational Diabetes
-
Middle East & Africa Diabetes Drugs Market, by Route of Administration
- Oral
- Injectable
-
Middle East & Africa Diabetes Drugs Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Specialty Clinics
- GCC Countries
- GCC Countries Diabetes Drugs Market, by Drug Class
- Insulin
- GLP-1 Receptor Agonists
- SGLT-2 Inhibitors
- DPP-4 Inhibitors
- Biguanides (Metformin)
- Others (Thiazolidinediones
- Meglitinides)
- GCC Countries Diabetes Drugs Market, by Diabetes Type
- Type 1 Diabetes
- Type 2 Diabetes
- Gestational Diabetes
- GCC Countries Diabetes Drugs Market, by Route of Administration
- Oral
- Injectable
- GCC Countries Diabetes Drugs Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Specialty Clinics
- GCC Countries Diabetes Drugs Market, by Drug Class
- South Africa
- South Africa Diabetes Drugs Market, by Drug Class
- Insulin
- GLP-1 Receptor Agonists
- SGLT-2 Inhibitors
- DPP-4 Inhibitors
- Biguanides (Metformin)
- Others (Thiazolidinediones
- Meglitinides)
- South Africa Diabetes Drugs Market, by Diabetes Type
- Type 1 Diabetes
- Type 2 Diabetes
- Gestational Diabetes
- South Africa Diabetes Drugs Market, by Route of Administration
- Oral
- Injectable
- South Africa Diabetes Drugs Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Specialty Clinics
- South Africa Diabetes Drugs Market, by Drug Class
-
Rest of Middle East & Africa
- Rest of Middle East & Africa Diabetes Drugs Market, by Drug Class
- Insulin
- GLP-1 Receptor Agonists
- SGLT-2 Inhibitors
- DPP-4 Inhibitors
- Biguanides (Metformin)
- Others (Thiazolidinediones
- Meglitinides)
- Rest of Middle East & Africa Diabetes Drugs Market, by Diabetes Type
- Type 1 Diabetes
- Type 2 Diabetes
- Gestational Diabetes
- Rest of Middle East & Africa Diabetes Drugs Market, by Route of Administration
- Oral
- Injectable
- Rest of Middle East & Africa Diabetes Drugs Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Specialty Clinics
- Rest of Middle East & Africa Diabetes Drugs Market, by Drug Class
-
Middle East & Africa Diabetes Drugs Market, by Drug Class
- North America
Vantage Market
Research | 04-Nov-2024
FAQ
Frequently Asked Question
What is the global demand for Diabetes Drugs in terms of revenue?
-
The global Diabetes Drugs valued at USD 84.65 Billion in 2024 and is expected to reach USD 177.74 Billion in 2034 growing at a CAGR of 7.7%.
Which are the prominent players in the market?
-
The prominent players in the market are Novo Nordisk, Sanofi, Bristol Myers Squibb, Eli Lilly and Company, AstraZeneca, Merck & Co., Johnson & Johnson, Pfizer, Novartis, Boehringer Ingelheim, AbbVie, Teva Pharmaceuticals, Glenmark Pharmaceuticals, Lupin Pharmaceuticals, Mylan N.V. (now part of Viatris)..
At what CAGR is the market projected to grow within the forecast period?
-
The market is project to grow at a CAGR of 7.7% between 2025 and 2034.
What are the driving factors fueling the growth of the market.
-
The driving factors of the Diabetes Drugs include
Which region accounted for the largest share in the market?
-
North America was the leading regional segment of the Diabetes Drugs in 2024.
